Abstract | BACKGROUND: OBJECTIVE: To evaluate the use of alicaforsen in clinical trials to understand its efficacy and side effects, as well as assess for evidence that may offer insight into disease pathways. METHODS: We evaluate all of the available, published trials, with a focus on the prospective, randomized trials. RESULTS/CONCLUSIONS: Systemic treatment for Crohn's disease has not revealed significant effect. Topical enemas for ulcerative colitis have demonstrated some effect in secondary outcomes, and initial studies in pouchitis are promising. In general, the compound has been well tolerated and safe.
|
Authors | Jessica R Philpott, Philip B Miner Jr |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 8
Issue 10
Pg. 1627-32
(Oct 2008)
ISSN: 1744-7682 [Electronic] England |
PMID | 18774928
(Publication Type: Journal Article)
|
Chemical References |
- Oligonucleotides, Antisense
- Phosphorothioate Oligonucleotides
- Intercellular Adhesion Molecule-1
- alicaforsen
|
Topics |
- Clinical Trials as Topic
- Humans
- Inflammatory Bowel Diseases
(drug therapy)
- Intercellular Adhesion Molecule-1
(metabolism)
- Oligonucleotides, Antisense
(therapeutic use)
- Phosphorothioate Oligonucleotides
(therapeutic use)
|